Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: BioHarvest Sciences Inc.

Market Cap 76.62M 66.04M 60.78M 57.01M 107M 7.24B 108M 718M 281M 3.55B 288M 281M 12.27B P/E Ratio 2026 *
-8.29x
P/E Ratio 2027 * -20.5x
Enterprise Value 76.62M 66.04M 60.78M 57.01M 107M 7.24B 108M 718M 281M 3.55B 288M 281M 12.27B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.3x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 68 29/04/2026
Director of Finance/CFO - 28/10/2024
Chief Operating Officer 65 19/04/2023
Director TitleAgeSince
Chairman 68 27/09/2018
Director/Board Member 67 27/09/2018
Director/Board Member 84 07/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%-2.94% - - 72.54M
-0.89%+1.31%-11.24%-6.10% 13.34B
-0.48%+1.31%-32.34%-55.94% 5.06B
-2.83%-0.10%-8.96%-0.99% 4.79B
+1.40%+5.50%+9.71%-40.16% 3.88B
+1.23%+0.70%+14.64%-14.85% 3.86B
-0.55%-2.25%-2.00%-7.86% 3.69B
+0.83%+3.86%-9.36%-0.27% 3.18B
+2.10%+5.07%-6.10%-25.40% 2.37B
+0.72%-2.83%-11.25%+29.03% 1.73B
Average +0.76%+1.65%-6.32%-13.62% 4.66B
Weighted average by Cap. -0.25%+1.61%-7.96%-14.84%

Financials

2026 *2027 *
Net sales 42.89M 36.97M 34.02M 31.92M 59.95M 4.05B 60.55M 402M 157M 1.99B 161M 158M 6.87B 58.96M 50.81M 46.77M 43.87M 82.41M 5.57B 83.23M 553M 216M 2.73B 221M 217M 9.44B
Net income -9.27M -7.99M -7.35M -6.89M -12.95M -876M -13.08M -86.89M -33.94M -429M -34.77M -34.03M -1.48B -3.77M -3.25M -2.99M -2.81M -5.27M -357M -5.33M -35.38M -13.82M -175M -14.16M -13.86M -604M
Net Debt - -
Logo BioHarvest Sciences Inc.
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.380USD
Average target price
12.75USD
Spread / Average Target
+277.22%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!